Funding for this research was provided by:
National Heart, Lung, and Blood Institute (OT3HL152448, OT3HL151434)
Article History
Accepted: 16 January 2023
First Online: 11 February 2023
Declarations
:
: This research was, in part, funded by the National Institutes of Health (NIH) Agreements OT3HL152448 and OT3HL151434. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.
: Dr. Aaron Winn reports consulting for Takeda Pharmaceuticals. Dr. Scott D. Ramsey reports consulting or advisory roles with Bayer Corporation, Bristol-Myers Squibb, AstraZeneca, Merck & Company Inc., Pfizer, Seattle Genetics, Biovica, GRAIL, and Genentech (institution); research funding from Bayer Corporation and Bristol-Myers Squibb; and travel accommodations or expenses from Bayer Schering Pharma, Bristol-Myers Squibb, GRAIL, and Bayer. The reported relationships may not relate to the subject matter of the article. The authors have no other disclosures to report.
: This study received ethics approval from the University of Washington.
: All authors contributed to the development of the model framework and to the writing and editing of the manuscript. AW provided Fig. InternalRef removed and Tables InternalRef removed, InternalRef removed, InternalRef removed. All authors have read and approved of the final manuscript.
: Not applicable.
: Not applicable.
: We will publish the results of this study in a peer reviewed journal, which will include publishing the equations of the simulation model to ensure others are able to use them.
: Code is available upon request.